Status:
ACTIVE_NOT_RECRUITING
Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients
Lead Sponsor:
Ain Shams University
Collaborating Sponsors:
National Heart Institute in Egypt
Misr International University
Conditions:
Heart Failure - NYHA II - IV
Cardiac Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
Heart failure with reduced ejection fraction (HFrEF) is a significant cause of morbidity and mortality. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated efficacy in improving renal...
Detailed Description
Heart failure is broadly classified into two main types based on the left ventricular ejection fraction (LVEF): heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ej...
Eligibility Criteria
Inclusion
- Adults (≥18 years) with HFrEF (LVEF ≤40%).
- Initiation of SGLT2 inhibitor therapy.
- Stable background HF therapy for at least 4 weeks.
- Written informed consent for participation and genetic testing.
Exclusion
- Known hypersensitivity to SGLT2 inhibitors.
- History of ketoacidosis or recurrent urinary tract infections.
- End-stage renal disease (eGFR \<30 mL/min/1.73 m²).
- Life expectancy \<6 months due to non-cardiovascular conditions.
- Pregnancy or lactation.
Key Trial Info
Start Date :
November 22 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06901609
Start Date
November 22 2023
End Date
July 1 2025
Last Update
March 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Heart Institute
Cairo, Egypt, 11315